This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| SLCO1B1 | |
|---|---|
| Name | SLCO1B1 |
| Other names | OATP1B1; OATP-C; SLC21A6 |
| Organism | Human |
| Gene symbol | SLCO1B1 |
| Chromosome | 12 |
SLCO1B1 is a human gene encoding an organic anion transporting polypeptide involved in hepatic uptake of diverse endogenous and xenobiotic compounds. The encoded protein functions at the basolateral membrane of hepatocytes to mediate transport of bilirubin, bile acids, hormones, and many drugs. Loss or alteration of this activity influences drug disposition and risk of adverse reactions, making the gene central to pharmacology, clinical genetics, and personalized medicine.
The protein mediates sodium-independent transport of organic anions into hepatocytes and participates in bilirubin clearance, bile acid handling, and steroid conjugate uptake. It contributes to enterohepatic circulation by moving substrates from plasma into the liver for metabolism and excretion. Disruption of transport affects plasma levels of statins, methotrexate, and rifampicin, altering therapeutic outcomes used in contexts such as World Health Organization treatment guidelines, Food and Drug Administration drug labeling, and clinical protocols at institutions like Mayo Clinic and Johns Hopkins Hospital. The transporter interacts functionally with hepatic enzymes including members of the Cytochrome P450 family and with other transporters such as members of the ATP-binding cassette transporter family.
The gene is located on chromosome 12 and belongs to the solute carrier organic anion (SLCO) family, sharing homology with other family members characterized in studies at laboratories affiliated with Harvard University, Stanford University, and the National Institutes of Health. The protein is predicted to have multiple transmembrane domains typical of OATP transporters; topology and conserved motifs were elucidated using approaches developed at Cold Spring Harbor Laboratory and by structural biology groups associated with the European Molecular Biology Laboratory. Amino acid residues implicated in substrate recognition and glycosylation sites were mapped through mutagenesis work performed in centers such as University of Cambridge and University of Tokyo.
Expression is predominantly hepatic, concentrated at the sinusoidal membrane of hepatocytes, with developmental regulation reported in fetal versus adult liver samples analyzed by consortia like the Human Genome Project and the ENCODE Project. Transcriptional control involves nuclear receptors and transcription factors profiled in studies from Massachusetts Institute of Technology and University of California, San Francisco, including regulation by pregnane X receptor and constitutive androstane receptor pathways highlighted in research related to United States National Library of Medicine resources. Post-translational regulation, trafficking, and degradation have been examined in labs collaborating with European Commission–funded networks and clinical centers such as Karolinska Institute.
Altered function is associated with altered pharmacokinetics and risk of drug-induced toxicity; clinical relevance has been integrated into practice guidelines from bodies like the Clinical Pharmacogenetics Implementation Consortium and safety communications from the European Medicines Agency. Variants are implicated in statin-associated myopathy and in cases of hyperbilirubinemia evaluated in tertiary care centers including Cleveland Clinic and Guy's and St Thomas' NHS Foundation Trust. Diagnostic assays and companion diagnostics used in precision medicine initiatives at institutions such as Dana-Farber Cancer Institute and Mayo Clinic inform therapeutic choices for agents metabolized by hepatic uptake pathways.
Common alleles produce reduced transporter activity and influence dosing and adverse-event risk for drugs such as simvastatin, pravastatin, and lopinavir used in regimens recommended by organizations like World Health Organization and Centers for Disease Control and Prevention. Pharmacogenetic testing recommendations have been debated in panels convened by entities including the Pharmaceutical Research and Manufacturers of America and the National Institute for Health and Care Excellence. Implementation studies in healthcare systems at Veterans Health Administration and academic centers such as University of Pennsylvania demonstrate impacts on prescribing and outcomes.
Notable single nucleotide polymorphisms show allele frequency differences among populations sampled in projects like the 1000 Genomes Project, HapMap Project, and population studies from institutions including University of Cape Town and Peking University. Population-specific risk stratification has been addressed in consortia spanning European Union multicenter cohorts and large biobanks such as the UK Biobank and the All of Us Research Program. Evolutionary analyses referencing methods from groups at Max Planck Society and Sanger Institute explore selective pressures and linkage disequilibrium patterns around the locus.
Functional characterization uses in vitro expression systems, hepatocyte cultures, and animal models developed in laboratories at Scripps Research Institute, The Rockefeller University, and industrial partners like GlaxoSmithKline and Pfizer. Knockout and transgenic mouse models created in facilities at Jackson Laboratory and the Wellcome Sanger Institute have elucidated physiological roles and drug interaction phenotypes. Ongoing clinical trials and translational studies coordinated by centers including National Cancer Institute and university hospitals continue to refine therapeutic strategies informed by SLCO1B1-associated transport biology.
Category:Human genes